Pharmakotherapie kognitiver Störungen der Alzheimer-Krankheit

Literatur

• 1 Aisen P S, Pasinetti G M. Glucocorticoids in Alzheimer"s disease. The story so far.  Drugs & Aging. 1998;  12 1-6
• 2 American Psychiatric Association .Diagnostic Criteria from the DSM-IV. American Psychiatric Press, Washington, DC 1994
• 3 American Psychiatric Association . Practice guideline for the treatment of patients with Alzheimer"s disease and other dementias of late life.  Am J Psychiatry. 1997;  154 (Suppl) 1-39
• 4 Ando Y, Suhr O, El-Salhy M. Oxidative stress and amyloidosis.  Histol Histopathol. 1998;  13 845-850
• 5 Avery E E, Baker L D, Asthana S. Potential role of muscarinic agonists in Alzheimer"s disease.  Drugs & Aging. 1997;  11 450-459
• 6 Birkhäuser M H, Strnad J, Kämpf C, Bahro M. Estrogens and Alzheimer’s disease.  Int J Geriatr Psychiatry. 2000; ;  im Druck
• 7 Cummings J L, Masterman D L. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer"s disease.  J Clin Psychiatry. 1998;  59 (Suppl) 23-30
• 8 Doody R S. Clinical profile of donepezil in the treatment of Alzheimer"s disease.  Gerontology. 1999;  45 (Suppl.) 23-32
• 9 Farlow M R, Evans R M. Pharmacologic treatment of cognition in Alzheimer"s dementia.  Neurology. 1998;  51 (Suppl.) S36-S44
• 10 Feldman R S, Meyer J S, Quenzer L F. Principles of Neuropsychopharmacology. Sinauer Associates Publishers, Sunderland, Massachusetts 1997
• 11 Felician O, Sandson T A. The neurobiology and pharmacotherapy of Alzheimer"s disease.  J Neuropsychiatry Clin Neurosci. 1999;  11 19-31
• 12 Flynn B L. Pharmacologic management of Alzheimer disease. Part I: Hormonal and emerging investigational drug therapies.  Ann Pharmacother. 1999;  33 178-187
• 13 Flynn B L, Ranno A E. Pharmacologic management of Alzheimer disease. Part II: antioxidants, antihypertensives, and ergoloid derivatives.  Ann Pharmacother. 1999;  33 188-197
• 14 Giacobini E. Aging, Alzheimer"s disease, and estrogen therapy.  Experimental Gerontology. 1998;  33 865-869
• 15 Hendrie H C. Epidemiology of dementia and Alzheimer"s disease.  Am J Geriatr Psychiatry. 1998;  6 S3-S18
• 16 Kumar V, Nalla U, Durai B, Jobe T. Pharmacologic management of Alzheimer"s disease.  Clinics in Geriatric Medicine. 1998;  14 129-146
• 17 Lawrence A D, Sahakian B J. The cognitive psychopharmacology of Alzheimer"s disease: Focus on cholinergic systems.  Neurochemical Research. 1998;  23 787-794
• 18 Levy M L, Cummings J L, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer"s disease.  Gerontology. 1999;  45 (Suppl) 15-22
• 19 Lynch G, Granger R, Ambros-Ingerson J, Davis C M, Kessler M, Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans.  Exp Neurol. 1997;  145 89-92
• 20 Meneses A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory.  Reviews in Neurosciences. 1998;  9 275-289
• 21 Nordberg A, Svensson A -L. Cholinesterase inhibitors in the treatment of Alzheimer"s disease. A comparison of tolerability and pharmacology.  Drug Safety. 1998;  19 465-480
• 22 Oken B S, Storzbach D M, Kaye J A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.  Arch Neurol. 1998;  55 1409-1415
• 23 Pitchumoni S S, Doraiswamy P M. Current status of antioxidant therapy for Alzheimer"s disease.  J Am Geriatr Soc. 1998;  46 1566-1572
• 24 Poirier J, Sévigny P. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer"s disease.  J Neural Transm. 1998;  53 (Suppl) 199-207
• 25 Richards S S, Hendrie H C. Diagnosis, management, and treatment of Alzheimer disease.  Arch Intern Med. 1999;  159 789-797
• 26 Rogers S L. Perspectives in the management of Alzheimer"s disease: Clinical profile of donepezil.  Dementia Geriatr Cogn Disord. 1998;  9 ( Suppl) 29-42
• 27 Rösler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer"s dementia: Currently available therapeutic strategies.  J Neural Transm. 1998;  54 (Suppl) 211-219
• 28 Shadlen M -F, Larson E B. What"s new in Alzheimer"s disease treatment? Reasons for optimism about future pharmacologic options.  Postgraduate Medicine/Alzheimer"s disease. 1999;  105 109-118
• 29 Sirviö J. Strategies that support declining cholinergic neurotransmission in Alzheimer’s disease patients.  Gerontology. 1999;  45 (Suppl) 3-14
• 30 Small G W, Rabins P V, Barry P P. et al . Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer"s Association, and the American Geriatrics Society.  JAMA. 1997;  278 1363-1371
• 31 Spencer C M, Noble S. Rivastigmine. A review of its use in Alzheimer"s disease.  Drugs & Aging. 1998;  13 391-411
• 32 Sunderland T, Molchan S E, Little J T, Bahro M, Putnam K T, Weingartner H. Pharmacologic challenges in Alzheimer disease and normal controls: Cognitive modeling in humans.  Alzheimer Disease and Associated Disorders. 1997;  11 (Suppl) S23-S26
• 33 Van Dongen M. Efficacy of Ginkgo biloba in dementia and cognitive decline. Proefschrift aan de Universiteit Maastricht 1999: 1-192
• 34 Volz H -P, Gleiter C H. Monoamine oxidase inhibitors. A perspective on their use in the elderly.  Drugs & Aging. 1998;  13 341-355
• 35 Weiner M F, Schneider L S, Gray K F, Stern R G. Pharmacological Management and Treatment of Dementia and Secondary Symptoms. In: Weiner MF (ed.): The Dementias - Diagnosis, Management, and Research. American Psychiatric Press, Washington, DC, London, Second Edition 1996: 175-210

Anhang

Einige Substanzklassen zur Behandlung der Alzheimer-Krankheit (Azetylcholinesterase-Hemmer) und nicht näher spezifizierter Demenzformen beziehungsweise Hirnleistungsstörungen im Alter (Nootropika)

Azetylcholinesterase-Hemmer

Donepezil (Aricept^®)

Rivastigmin (Exelon^®)

Tacrin  (Cognex^®)

Nootropika

Dihydroergotoxin (z. B. Hydergin^®)

Ginkgo biloba  (z. B. Rökan^®, Tebonin^®)

Nicergolin  (z. B. Sermion^®)

Piracetam  (Normabrain^®, Nootrop^®)

Pyritinol (z. B. Encephabol^®)

Korrespondenz